New BMJ Editorial out today from @rocher.lc and me: www.bmj.com/content/393/... - Biobank's response to the news that researchers have accidentally uploaded data to GitHub multiple times is insufficient & risks trust in the UK's health data ecosystem. Everyone needs to feel responsible for privacy.
Posts by Joseph Ross
New study in @jamanetworkopen.com this week: frequency of post-market safety issues for cancer drugs with accelerated approval.
Happy to collaborate on this study with Dr. Mooghali, @reshmagar.bsky.social @jsross119.bsky.social
jamanetwork.com/journals/jam...
Well worth the read ... subsidy cuts will be felt hardest in states that did not expand Medicaid as part of the ACA
Thanks @arnoldventures.bsky.social for supporting @yalecrrit.bsky.social - study builds on work nearly a decade ago published in @jama.com (jamanetwork.com/journals/jam...) - flagging for @alecgaffney.bsky.social @zacharybrennan.bsky.social @sarahkarlin-smith.bsky.social @lizzylawrence.bsky.social
Lots more detail in the paper (jamanetwork.com/journals/jam...), but our findings provide the first evaluation of FDAAA and its enhanced safety-related regulatory authorities, and its impact on drug safety and public health, and informs current PDUFA VII negotiations! @reshmagar.bsky.social (5/5)
... among therapeutics with postmarket safety-related actions within 5 years of approval, median time to first action was 1.3 years shorter post-FDAAA implementation, perhaps a consequence of FDAAA's conferring FDA new PMR authority and defined timelines for label changes (4/5)
Among these, FDA took postmarket safety-related actions for 23%, including actions within 5 years of approval for 21% approved pre-FDAAA and 14% approved post-FDAAA (p=.06). While FDAAA was not associated with differences in time to first postmarket safety-related action ... (3/5)
We wanted to understand whether FDAAA was associated with changes in FDA postmarket drug safety−related actions, and what characteristics were associated with a greater or lower likelihood of actions. To do this, we studied all 560 new drugs and biologics approved by FDA from 2001-2017 (2/5)
New paper from @yalecrrit.bsky.social out today in @jamainternalmed.com - The 2007 US Food and Drug Administration (FDA) Amendments Act (FDAAA) expanded the agency's safety-related regulatory authorities, including enhanced postmarketing safety surveillance and new clinical study requirements (1/5)
Here's our new article reporting findings from stakeholder interviews in which we hoped to learn what it takes to successfully complete rigorous confirmatory studies after accelerated approval. Instead, we mostly heard willingness to trade rigor for feasibility. 1/
academic.oup.com/healthaffair...
See recent articles in @jama.com, such as jamanetwork.com/journals/jam..., jamanetwork.com/journals/jam..., and jamanetwork.com/journals/jam... @lisamjarvis.bsky.social
Most early attention on the H-1B EO imposing a $100k fee is focused on the tech industry (i.e., good story by @joshwingrovebbg.bsky.social and Spencer Soper) www.bloomberg.com/news/article.... However, this policy will have a huge impact on healthcare delivery systems and research enterprise (1/2)
"Climate change is no longer a problem for our grandchildren but is inflicting profound economic and health damage right now.” @markgongloff.bsky.social
Kudos to @fda.gov leadership for following through on their efforts to promote transparency by posting CRLs for 2024 pending or withdrawn product applications. There is a lot that scientists, industry and clinicians can learn when FDA does not approve a product www.fiercebiotech.com/biotech/fda-...
Great reporting on RFK "going wild" by sabotaging the @altcdc.altgov.info @dhruvkhullar.bsky.social www.newyorker.com/magazine/202...
Florida Made a Vaccine Mistake. Now, It’s Everyone’s Problem.
Agree with @lisamjarvis.bsky.social, viruses don’t give a damn for state lines
www.bloomberg.com/opinion/arti...
Great story by @annaedney.bsky.social ... reminds me of what happened with Essure, as patients complaints went unheeded for years
"The American scientific enterprise is being unravelled before our eyes—research grants are being cut off, satellites disconnected, reports cooked up [by] particular industries and ideologies ... but in the end, the truth will [win] out." @billmckibben.bsky.social www.newyorker.com/news/the-led...
“Physicians receiving payments were more likely to prescribe the company's drugs, with a stronger association for payments that were larger, sustained and recent.”
New work on bribes to Rx multiple sclerosis drugs by Sayed, @reshmagar.bsky.social @jsross119.bsky.social
"In a world accustomed to receiving real-time information, the process of publishing medical research remains trapped in a system designed for a slower era,” per @jsross119.bsky.social & colleagues from @utoronto.ca Med in @annalsofim.bsky.social
www.acpjournals.org/doi/10.7326/...
#peerreview
Amazing data visualization illustrating how Grier family manipulated science to ‘prove’ vaccines cause autism. Key take-home: "those who claim to champion people with autism are denying them real research while undermining one of public health’s greatest achievements" www.nytimes.com/interactive/...
The EPA's disastrous plan to end the regulation of greenhouse gases & just let climate change run rampant. www.newyorker.com/news/the-led... via @elizkolbert.bsky.social
1. On February 24, Extremity Care LLC, a company that sells very expensive bandages made from placentas, donated $5 MILLION TO TRUMP'S SUPER PAC
Days later, Trump froze a pending rule that would BAR MEDICARE FROM COVERING EXTREMITY CARE'S PRODUCTS, which are overpriced & not backed by science.
"The esteemed climate scientist Michael Mann said the report was akin to the result he would expect “if you took a chatbot and you trained it on the top 10 fossil fuel industry-funded climate denier websites”."
www.theguardian.com/us-news/2025...
I have a new post over at The Climate Brink on how the recent DOE report on climate science and the EPA's proposed overturning of the endangerment finding used and misused my research: www.theclimatebrink....
"If the US is no longer the world’s technoscientific superpower, it will almost certainly suffer for the change. America’s technology sector might lose its creativity. But science itself, in the global sense, will be fine. The deep human curiosities that drive it do not belong to any nation-state."
A singular achievement in reporting and storytelling: The Men Trump Deported to a Salvadoran Prison, by @propublica.org and partners.
High brand-name drug prices fall once a generic enters the market. In a new @journalgim.bsky.social article, Ravi Gupta, CRRIT Co-Director @jsross119.bsky.social, and colleagues from @portalresearch.org assess associations between patents, revenue, and generic competition.
You cannot make this stuff up! @muskwatch.bsky.social reports that Musk's $9b neurotechnology company self-certified as a "small disadvantaged business", despite his >$400b net worth, and federal regs precluding designation to individuals with a net worth >$850k www.muskwatch.com/p/musks-neur...